Daiichi Sankyo’s Growth Plan Is Built On ADCs

 
• By Jessica Merrill
  
Generate a summary of this article
Listen to this article
Beta

The Japanese pharma has established itself as an early leader in antibody-drug conjugates (ADCs) for cancer. Global oncology business head Ken Keller talked to Scrip about the portfolio, pipeline and deals.

growth plan
Daiichi Sankyo is on a solid growth trajectory. • Source: Shutterstock

Once known as a cardiovascular drug developer, Daiichi Sankyo has attained credibility in oncology, especially outside of its home base of Japan. The company’s emergence as an early leader in the development of antibody-drug conjugates (ADCs) for cancer has led to two lucrative licensing deals with big pharma partners spanning five products, each with potential in multiple indications, and reshaped the company’s growth potential.

Key Takeaways

  • Oncology is poised to make up nearly half of Daiichi Sankyo’s sales by 2025, up from around 30% currently.

Oncology is poised to make up nearly half of Daiichi Sankyo’s sales by 2025, up from around 30% currently, global...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Anticancer

Fosun ALK/ROS1 Inhibitor Shows 1L Promise In Advanced NSCLC

 
• By Xu Hu

Interim results from the Phase III REMARK study presented at WCLC showed the Chinese company’s second-generation ALK/ROS1 inhibitor met its primary endpoint as a first-line therapy in ALK-positive advanced NSCLC.

Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]

Pipelines in bioconjugates continue to develop, from ADCs to XDCs, with radionuclide drug conjugates (RDCs) and antibody-oligonucleotide conjugates (AOCs) leading the expansion.

Fosun ALK/ROS1 Inhibitor Shows 1L Promise In Advanced NSCLC

Interim results from the Phase III REMARK study presented at WCLC showed the Chinese company’s second-generation ALK/ROS1 inhibitor met its primary endpoint as a first-line therapy in ALK-positive advanced NSCLC.

Allarity Hopes To Breathe New Life Into Ixempra In Breast Cancer

The US precision medicine company hopes its drug response predictor technology will enhance responses to the chemotherapy Ixempra on the basis of promising data from a handful of breast cancer patients in a Phase II trial, marking a positive turn in its journey to date.  

More from Therapeutic Category

Scrip Data Article Without An Author

"Neque porro quisquam est qui dolorem ipsum quia dolor sit amet, consectetur, adipisci velit..."

Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]

Pipelines in bioconjugates continue to develop, from ADCs to XDCs, with radionuclide drug conjugates (RDCs) and antibody-oligonucleotide conjugates (AOCs) leading the expansion.

Fosun ALK/ROS1 Inhibitor Shows 1L Promise In Advanced NSCLC

Interim results from the Phase III REMARK study presented at WCLC showed the Chinese company’s second-generation ALK/ROS1 inhibitor met its primary endpoint as a first-line therapy in ALK-positive advanced NSCLC.